Concepedia

Alexandre V. Hirayama

AV

Statistics

Publications

22

Citations

2.7K

H-Index

19

Active since

2018

Affiliations

Fred Hutch Cancer Center(Current)

University of Washington

University of British Columbia

Seattle Children's Hospital

Oregon Health & Science University

Alexandre V. Hirayama is an author at Fred Hutch Cancer Center specializing in chimeric antigen receptor t-cell therapy, immunotherapy, and immunology.

ORCID

Publications per year

2018–2025

22

Publications

22

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

Kevin A. Hay, Jordan Gauthier, Alexandre V. Hirayama et al. · Blood · 2019 · 401 citations · Full text

, , +13

Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells

Ana Cordeiro, Evandro D. Bezerra, Alexandre V. Hirayama et al. · Biology of Blood and Marrow Transplantation · 2019 · 351 citations · Full text

, , +9

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Alexandre V. Hirayama, Jordan Gauthier, Kevin A. Hay et al. · Blood · 2019 · 336 citations · Full text

, , +14

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

Jordan Gauthier, Alexandre V. Hirayama, Janaki Purushe et al. · Blood · 2020 · 320 citations · Full text

, , +16

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Jordan Gauthier, Evandro D. Bezerra, Alexandre V. Hirayama et al. · Blood · 2020 · 212 citations · Full text

, , +13

1–5 of 22